Clinical Trial Update: MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial MOVING evaluating modification of visual outcomes after optic neuritis in CIS or MS using Gilenya; terminated study phase 2/3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Multiple Sclerosis | Phase 2, Phase 3 | Status: TERMINATED